TY - JOUR T1 - Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW SP - 1 LP - 9 DO - 10.1183/09059180.00010701 VL - 17 IS - 107 AU - J. Bousquet AU - U. Wahn AU - E. O. Meltzer AU - H. Fox AU - S. Hedgecock AU - K. Thomas AU - A. Fowler-Taylor Y1 - 2008/04/01 UR - http://err.ersjournals.com/content/17/107/1.abstract N2 - Immunoglobulin E (IgE) is central to the development of allergic diseases. Cross-linking of cell-bound IgE by the allergen leads to the initiation of the inflammatory cascade. Omalizumab, an anti-IgE antibody, forms complexes with free IgE, thereby inhibiting the allergic reaction before its commencement. A survey of the clinical trials performed on omalizumab indicated that this anti-IgE antibody is efficacious and well tolerated in the treatment of separate and concomitant asthma and rhinitis. In patients with poorly controlled asthma, omalizumab reduced the asthma exacerbation and emergency visit rate, along with improving the quality of life. The improvement in asthma control was associated with a reduction of inhaled and oral corticosteroids. Improved nasal symptom scores and a reduced need for antihistamines were observed in patients with allergic rhinitis. Omalizumab was also proven to be effective as an add-on therapy for concomitant asthma and rhinitis. In conclusion, omalizumab provides an integrated approach for the treatment and management of allergic respiratory diseases. ER -